Preview

Oxyglobin Case

Good Essays
Open Document
Open Document
621 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Oxyglobin Case
What price and Why?

To assess what price Oxyglobin should be set at, we must analyze the 4 C's. Firstly, in evaluating the company, we determine that the cost of production is $15 Million per year independent of volume, plus $1.50 per unit variable cost. The current capacity for Oxyglobin is 300,000 units. In exhibits 4 and 5 we determine their break-even cost.

Next, we must determine who the customer is and what their potential is. To do this, we begin by looking at the number of veterinary practices in the US. Exhibit 1 shows the average monthly case load of the 15,000 US veterinary practices. In looking at these averages, we can determine the absolute number of practices and doctors for each class of practice. Taking the average number
…show more content…
Targeting veterinarians in the emergency care segment is the most efficient and effective approach. The potential of this segment is 6,930,000 animals per year. Of this nearly 7 Million animals in need of blood, approximately 7 % of the need blood come from blood banks and the remaining 93% from a very inefficient and costly "donor animal". This 93% (6,444,900) represent the potential market for Oxyglobin and is clearly far above the 300,000 unit annual capacity for Oxyglobin. Conservatively, if we assume 30% of these animals are in critical need of blood then we get 2,079,000 animals. Of this population, we know that 60% of Veterinarians and 65% of pet owners are willing to pay the $200, $400 (vets cost doubled to pet owner) price. Again, being conservative, if only 25% are actually willing to pay those prices, we still have a demand of 519,750, again far exceeding our capacity. Exhibits 2 and 3 represent the willingness of vets and owners to pay Oxyglobin at various price points. From this we can derive our estimated total revenue assuming both unlimited …show more content…
To distribute Oxyglobin through a regional or national network would require a commission to the distributor of 20% to 30% of the selling price. At $200 and 300,000 units, this would be between $9,000,000 and $13,500,000. It is more cost effective for Biopure to sell directly to the veterinary practices. This manufacturer direct model (Exhibit 4) will require Biopure to recruit and maintain a sales force of approximately 10 employees (at an estimate total cost of $100,000 per) and carries a $10-$15 distribution cost per unit. With 750 emergency practices, each sales person would be assigned 75 practices. At 300,000 units the distribution cost is $4,500,000 on the high end and our staff costs and administration costs an additional $1,000,000. Therefore, our $5,500,000 cost is more favorable to the $9-13.5 Million for an independent distributor and is built into our $200

You May Also Find These Documents Helpful

  • Satisfactory Essays

    #4 How many incremental daily visits would it take to pay for the marketing program, irrespective of overall clinic profitability?…

    • 964 Words
    • 4 Pages
    Satisfactory Essays
  • Satisfactory Essays

    Biopure needs to determine the best course of action to launch two new products, Oxyglobin a blood substitute for the veterinary market and Hemopure a blood substitute for the human market. Oxyglobin has been approved for commercial use and is ready for launch while Hemopure is expected to be FDA approved within two years. Biopure needs to decide whether and when to launch Oxyglobin. If decided to launch, the ability to price Oxyglobin appropriately is critical to minimize the impact of prospective launch for Hemopure. We believe Oxyglobin should be launched immediately because…

    • 1016 Words
    • 5 Pages
    Satisfactory Essays
  • Powerful Essays

    Student

    • 1579 Words
    • 7 Pages

    We must assume the estimates for short-run cost functions to determine the profit-maximizing output level to be accurate based on previous calculations provided by BioMed. This information is also used to determine the optimal size for the new unionized workforce. As we have been advised the company is in a…

    • 1579 Words
    • 7 Pages
    Powerful Essays
  • Powerful Essays

    Zoecon Corporation Essay

    • 857 Words
    • 4 Pages

    $ Sales for Initial Trial: 22 million HH x 6% trial rate x 1.3 units x $4.32/unit = $7,413,120.00…

    • 857 Words
    • 4 Pages
    Powerful Essays
  • Good Essays

    First, Biopure has to concentrate on the emergency care market instead of primary care market since the research shows relatively higher gross revenue in emergency care practices despite the rare 5% frequency. In addition, the annual requirement of blood transfusion in emergency care practices is approximately 900,900 units, which exceed 300,000 units – the capacity of Oxyglobin. In other words, the whole Oxyglobin can be successfully sold out because of the deficit blood supply. Furthermore, pet owners are more willing to pay for emergency care than pay for primary care. Therefore, Biopure can only focus its target on emergency care practices market in the initial stage. Second, $150 per unit is a proper price for Oxyglobin because of the results offered by the pet owners’ and veterinarians’ surveys. The results indicated that $150 and $300 per unit are willingly accepted by veterinarian and pet owner when most clients face critical cases. Aside from that, a pet owner will pay $130 to $170 per unit in a typical emergency care practice under the “donor animal” system. Oxyglobin at $150 can…

    • 616 Words
    • 3 Pages
    Good Essays
  • Powerful Essays

    Khalideoq

    • 815 Words
    • 4 Pages

    As the production manager, you need to minimize both ordering and inventory costs. You need to provide a recommendation of the optimal order quantity of raw materials to your plant manager. Your objective is to determine the economic order quantity (EOQ). If the annual demand for Ultamyacin at Smitheford is 400,000 units, then the annual carrying cost rate is 15% of the cost of the unit. The product costs $48/unit to purchase, and the product ordering cost is $28.00".…

    • 815 Words
    • 4 Pages
    Powerful Essays
  • Good Essays

    Momentaa

    • 712 Words
    • 3 Pages

    While the number of people owning cats and dogs in Canada has grown about one to two per cent per year, in the past few years, the Canadian pet industry has presented an average growth of 3.6% per year for several years, considering food, supplies, and services. Considering that Momentaa offers high quality and unique product, the range of competitors is narrowed compared with low cost products. However, this industry is growing fast, driven by the “premiumization and humanization” of pets over the years, leading to pet owners to spend more on their pets, buying more high-end accessories, higher quality foods, and more expensive medical treatments. ,…

    • 712 Words
    • 3 Pages
    Good Essays
  • Good Essays

    Although the ranchers appreciate the visits and the personal attention from the sales representatives they trust their veterinarians’ opinion over everyone else. Pfizer has traditionally used two distribution channels for its Animal Health products: Veterinarian Offices and Feed Stores. It has also tended to view the rancher as the end user of its product, but due to the size segmentation it may or may not understand each individual customers need, nor does it grasp its role in the larger supply chain (Ranchers-Feed Lots-Meat Packers-Retail-Consumers).…

    • 1018 Words
    • 5 Pages
    Good Essays
  • Better Essays

    The premium pet products and services market is growing to be very large. There is a group…

    • 2411 Words
    • 10 Pages
    Better Essays
  • Satisfactory Essays

    medlmmune report

    • 780 Words
    • 4 Pages

    In United States, flu vaccine market is dominated by three companies producing about 80 million does every year. Entry barrier level is extremely high because of the advanced technology involved and complicated legal procedures. So far, despite FluMist, which is a brand new type of flu vaccine, there is no substitute for traditional vaccine. Before the launch of FluMist, buyer power is low because they can only consume traditional vaccine, which is offered at similar prices at most places. (Appx. B) MedImmune, who is about to introduce FluMist, owns the patent of this new technology, which eliminates competitions. The occasional shortage in the past is a perfect opportunity for FluMist to get into the market, since consumers would be forced to try this new vaccine because there will be no other options. On the other hand, they are able to define a new market segment with those afraid or choose not to take injection when possible. However, the cost of FluMist is almost two times higher than traditional vaccine; when it is produced at a lower volume, direct product cost can go up to more than $15. Furthermore, the market is limited to the population that is healthy from 5 to 49; the vaccination rate is only 10% in this population. (Appx. A)…

    • 780 Words
    • 4 Pages
    Satisfactory Essays
  • Powerful Essays

    Biopure Case Study

    • 2639 Words
    • 11 Pages

    In 1998, Biopure Corporation is one of the three legitimate contenders in the emerging field of “blood substitutes” along with Baxter International and Northfield Laboratories. Many opportunities are available in the human blood market due to several disadvantages of the currently available alternatives. Biopure has invested $200M on the R&D of blood substitutes with its primary goal being the development of a human blood substitute, Hemopure. It has recently received FDA approval for Oxyglobin, a blood substitute for the veterinary market, whereas Hemopure will enter phase 3 clinical trials and is expected to get FDA approval by late 1999. Biopure is now faced with the big decision on whether to launch Oxyglobin now and reap the near-term benefits or wait till Hemopure is approved and established in the market. The following analysis examines the current market demand for the human and veterinary blood substitutes, the competitive environment, the pricing strategy for Oxyglobin and how it will impact the future launch of Hemopure.…

    • 2639 Words
    • 11 Pages
    Powerful Essays
  • Good Essays

    The income from Oxyglobin can also benefit in the advertising, promotion and the sales force needed to sell Hemopure once it is ready to be released. Since Hemopure’s blood substitute will be targeting a much larger market, the advertising and education of the product will be more extensive and more expensive. In terms of the sales force, Biopure will need highly educated and skilled people to…

    • 1208 Words
    • 4 Pages
    Good Essays
  • Powerful Essays

    Biopharma Case Study

    • 1265 Words
    • 6 Pages

    As of 2009, BioPharma is looking to reduce costs across the board. Profits have been steeply declining while production costs are high, especially at its German and Japanese facilities. With exception of India, demand is expected to remain relatively stable for the short-term future, so BioPharma can no longer afford its costly surplus capacity. BioPharma produces and sells two chemicals in bulk. Each plant they currently have is capable of producing both chemicals. They are willing to idle production at the Germany and Japan plants on one or both chemicals in order to reduce costs. They are also willing to reallocate which plant makes how much of each chemical and where they are distributed to.…

    • 1265 Words
    • 6 Pages
    Powerful Essays
  • Satisfactory Essays

    Biopure

    • 1060 Words
    • 5 Pages

    Biopure has two new products namely Oxyglobin and Hemopure. Oxyglobin is a first of its kind, new blood substitute for the veterinary market and has passed all the tests and is ready for consumer use. Hemopure is another such blood substitute for the human market and it will take a minimum of two years to launch the product from now. There is a concern about creating an unrealistic price expectation for Hemopure by marketing Oxyglobin before Hemopure. Whereas another point of view is that selling Oxyglobin will benefit the company by generating revenues that could be utilized while launching Hemopure and also in gaining valuable experience as to how to market and avoid the same errors while launching Hemopure. There are many other advantages of launching Oxyglobin early which have been clearly stated in the analysis that follows.…

    • 1060 Words
    • 5 Pages
    Satisfactory Essays
  • Better Essays

    Biopure Case

    • 1638 Words
    • 7 Pages

    BioPure Corporation, which was founded in 1984 by entrepreneurs Carl Rausch and David Judelson, is a privately owned biopharmaceutical firm specializing in the ultra purification of proteins for human and veterinary use. In 1998 Biopure pioneered the development of oxygen therapeutics using "Hemoglobin", a new class of pharmaceuticals that are intravenously administered to deliver oxygen to the body's tissues. Biopure's two products, Hemopure for human use, and Oxyglobin for animal veterinary use, both represented a new Oxygen based treatment approach for managing patients' oxygen requirements in a broad range of potential medical applications. The factor distinguishing Biopure's two products from other blood substitute products being developed by two possible rivals, Baxter International and Northfeild Laboratories, is that its hemoglobin based source is bovine rather than human and was derived from the blood cells of cattle. Both of Biopure's blood substitute products were in the final stages of the approval process of the Food and Drug Administration (FDA) in 1998. Oxyglobin had just received the FDA's approval for commercial release declaring it safe and effective for medical use. Hemopure was entering final Phase 3 clinical trials and was optimistically expected to see final FDA approval for release in 1999. The FDA approval of Oxyglobin and its possible subsequent release into the veterinary market caused concern over whether the early release of Hemoglobin would impinge BioPure's ability to price Hemopure when the product finally received approval. Given that the two products were almost identical in properties and function, it was thought that the early release of Oxyglobin would create an unrealistic price expectation for Hemopure if released first.…

    • 1638 Words
    • 7 Pages
    Better Essays